EN
Executive Summary: Treating Tauroursodeoxycholic Acid (TUDCA) and Ursodeoxycholic Acid (UDCA) as interchangeable commodities is a critical regulatory and procurement mistake. TUDCA is the taurine-conjugated, highly hydrophilic derivative of UDCA. Sourcing teams must lock exact CAS registry numbers, separate analytical HPLC assay methods, and market-compliant label terminology before issuing purchase orders.
Supplier quotations often list "UDCA/TUDCA" with a slash, implying that the two ingredients are interchangeable or mere grade variations of the same compound. Your product brief specifies TUDCA. The supplier COA reports a generic peak without separating unconjugated precursors. Procurement approves the shipment, only for regulatory reviewers to flag major discrepancy between the raw material specification, finished product label, and commercial invoice.
TUDCA and Ursodeoxycholic Acid (UDCA) are closely related bile acids, but they represent fundamentally distinct purchasing items. Sourcing bulk TUDCA raw material powder requires rigorous distinction from pharmaceutical UDCA to ensure lawful compliance across OEM dietary supplement capsules.
1. Chemical Distinction: Free Bile Acid vs. Taurine Conjugate
The molecular difference between TUDCA and UDCA fundamentally alters polarity, aqueous solubility, and formulation behavior:
2. Why "TUDCA/UDCA" on a Quotation is a Severe Red Flag
Suppliers who combine "TUDCA/UDCA" into a single search keyword often attempt to market UDCA raw materials or crude synthetic intermediates under the premium price tier of finished TUDCA. A specification stating only "Ursodeoxycholic Acid Equivalent" is legally insufficient for a finished TUDCA dietary supplement product.
To ensure purity and regulatory safety, require suppliers to submit baseline-resolved Reversed-Phase HPLC chromatograms separating TUDCA ($R_t pprox 8.2 ext{ min}$) from free unconjugated UDCA ($R_t pprox 14.5 ext{ min}$) with individual impurity limits set to $\le 0.5\%$.
3. The Evidence Chain: Do Not Borrow UDCA Drug Claims
Clinical studies evaluating prescription UDCA for cholestatic conditions cannot be legally borrowed to support dietary supplement structure/function claims for TUDCA. Brand owners must construct an independent claim-to-evidence dossier verifying:
- Exact clinical study material was Tauroursodeoxycholic Acid, not unconjugated UDCA;
- Commercial batch assay ($\ge 98.0\%$) and related bile acid thresholds match pre-clinical specifications;
- Supplement facts label declares true TUDCA active weight without generic bile salt wording.
Lock Pure TUDCA Active Raw Materials & Finished Formulations
Shaanxi Rainwood Biotech provides certified bulk TUDCA powder (CAS 14605-22-2) and custom TUDCA capsule manufacturing backed by full HPLC impurity profiling and third-party ISO 17025 COA verification.
Frequently Asked Questions (FAQ)
Q1: Can a dietary supplement brand sell UDCA instead of TUDCA?
In the United States and European Union, UDCA is regulated as a prescription drug (API). Selling UDCA in a dietary supplement violates federal drug regulations. TUDCA, as a dietary ingredient, must be explicitly specified and verified.
Q2: What is the primary difference in physiological solubility between TUDCA and UDCA?
Taurine conjugation imparts a strong negative charge to TUDCA at physiological pH, rendering it significantly more water-soluble and non-toxic to cell membranes compared to hydrophobic UDCA.
Q3: How do buyers ensure a supplier is delivering pure TUDCA?
Require a batch-specific COA referencing CAS 14605-22-2, HPLC potency ($\ge 98.0\%$), and specific testing showing free unconjugated UDCA is strictly below 0.5%.
References & Standards
- PubMed Central (PMC): Tauroursodeoxycholate—Bile Acid with Chaperoning Activity (PMC6952947)
- US FDA: Dietary Supplement Labeling Guide (21 CFR Part 101).
- Shaanxi Rainwood Biotech: Bulk TUDCA Specifications and OEM Formulation Dossiers.